scPharmaceuticals Inc. (SCPH): Price and Financial Metrics

scPharmaceuticals Inc. (SCPH): $6.00

0.05 (+0.84%)

POWR Rating

Component Grades













SCPH Stock Price Chart Interactive Chart >

Price chart for SCPH

SCPH Price/Volume Stats

Current price $6.00 52-week high $9.64
Prev. close $5.95 52-week low $4.75
Day low $5.78 Volume 66,900
Day high $6.51 Avg. volume 102,458
50-day MA $5.78 Dividend yield N/A
200-day MA $6.24 Market Cap 164.13M

scPharmaceuticals Inc. (SCPH) Company Bio

scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.

SCPH Latest News Stream

Event/Time News Detail
Loading, please wait...

SCPH Latest Social Stream

Loading social stream, please wait...

View Full SCPH Social Stream

Latest SCPH News From Around the Web

Below are the latest news stories about scPharmaceuticals Inc that investors may wish to consider to help them evaluate SCPH as an investment opportunity.

scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021

Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group Company on track to resubmit FUROSCIX NDA in the fourth quarter 2021 BURLINGTON, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies

Yahoo | September 10, 2021

scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

Intrado Digital Media | September 1, 2021

Are Institutions Heavily Invested In scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shares?

Every investor in scPharmaceuticals Inc. ( NASDAQ:SCPH ) should be aware of the most powerful shareholder groups...

Yahoo | August 23, 2021

scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX ® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4

Intrado Digital Media | August 11, 2021

scPharma''s Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients

scPharmaceuticals Inc (NASDAQ: SCPH ) announced top-line results from its FREEDOM-HF study evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure. Patients were treated with the Company''s investigational Furoscix, post-discharge from the emergency department, compared to a historical comparator group treated with intravenous furosemide in the inpatient hospital setting. Due to a Full story available on

Benzinga | July 14, 2021

Read More 'SCPH' Stories Here

SCPH Price Returns

1-mo 21.70%
3-mo 14.72%
6-mo -9.23%
1-year -19.57%
3-year 17.65%
5-year N/A
YTD 13.42%
2020 -6.54%
2019 50.53%
2018 -68.90%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7488 seconds.